Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239368 | 1.00 | MAPK1 (0.35) | MAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL15813670 | 1.00 | MAPK1 (0.35) | MAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL26016352 | 1.00 | MAPK1 (0.35) | MAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL20250956 | 1.00 | MAPK1 (0.35) | MAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL20250955 | 1.00 | MAPK1 (0.35) | MAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL16017770 | 1.00 | MAPK1 (0.35) | MAPK1ALDH1A1MEN1KMT2A | |
| Water SCHEMBL9448565 | 0.97 | MAPK1 (0.33) | MAPK1ALDH1A1MEN1KMT2A | |
| Ethylene SCHEMBL3275731 | 0.94 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL237181 | 0.89 | MAPK1 (0.40) | MAPK1ALDH1A1 | |
| SCHEMBL20436939 | 0.88 | CYP4F2 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230323027-A1 | POLYMERISATION PROCESS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-10-12 | — | — | US | disclosed |
| US-11739223-B2 | Surface primer compositions and methods of use | ENVISTA (US) | 2023-08-29 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| CN-109704930-A | The method and fuel oil additive of high selectivity dihydric alcohol di-tert-butyl ether | 深圳市前海博扬研究院有限公司 | 2019-05-03 | — | — | CN | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-7915524-B2 | Sealing agent for photoelectric conversion device and photoelectric conversion device using the same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20080274305-A1 | Liquid Crystal Sealant and Liquid Crystal Display Cell Utilizing the Same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-11-06 | — | — | US | disclosed |
| CN-100407494-C | Sealing agent for photoelectric conversion element and photoelectric conversion element using the same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-07-30 | — | — | CN | disclosed |
| US-7101596-B2 | Liquid crystal sealant, liquid crystal display device using the same and method for producing the device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2006-09-05 | — | — | US | disclosed |
| US-20060162771-A1 | Sealing agent for photoelectric conversion element and photoelectric conversion device element using the same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1674919-A1 | SEALANT FOR LIQUID CRYSTAL, LIQUID-CRYSTAL DISPLAY MADE WITH THE SAME, AND PROCESS FOR PRODUICNG THE DISPLAY | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-06-28 | — | — | EP | disclosed |
| CN-1751410-A | Sealing agent for photoelectric conversion element and photoelectric conversion element using the same | NIPPON KAYAKU KK (JP) | 2006-03-22 | — | — | CN | disclosed |
| EP-1598897-A1 | SEALING AGENT FOR PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTRIC CONVERSION ELEMENT USING THE SAME | Nippon Kayaku Kabushiki Kaisha (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-20050181145-A1 | Liquid crystal sealant, liquid crystal display device using the same and method for producing the device | SHARP KABUSHIKI KAISHA (JP) | 2005-08-18 | — | — | US | disclosed |
| US-6120858-A | COMPRISING AN EPOXY RESIN, A NOVOLAC RESIN, A CURING ACCELERATOR AND A TITANIUM BLACK PIGMENT | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | MAPK1 3924/4885ALDH1A1 3671/4885MEN1 727/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | MAPK1 772/4885ALDH1A1 2211/4885MEN1 2168/4885 |
| US-11739223-B2 | Surface primer compositions and methods of use | SP1, GPER1, GRIN1 | MAPK1 1711/4885ALDH1A1 1177/4885MEN1 4073/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | MAPK1 4023/4885ALDH1A1 2567/4885MEN1 3483/4885 |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | CDK3, CDK4, CDK1 | MAPK1 523/4885ALDH1A1 4096/4885MEN1 3241/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | MAPK1 4161/4885ALDH1A1 3688/4885MEN1 1376/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | MAPK1 3924/4885ALDH1A1 3671/4885MEN1 727/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | MAPK1 3128/4885ALDH1A1 3412/4885MEN1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.